Finance

Lists
Outlook: 41.4% bullish·5.4% bearish
Go to analysis
JNJ:NYSE
Johnson & Johnson
$253.79
-0.69%
(-1.77) 1D
$252.85
-0.37% (-0.94)
After hours
Closed: Oct 19, 4:00:08 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JNJ...
Open
$254.43
High
$255.56
Low
$251.50
Mkt. cap
611.61B
Avg. vol.
7.09M
Volume
8.68M
Dividend
2.11%
Quarterly dividend
$1.34
Ex-dividend date
Aug 25, 2026
P/E ratio
38.52
52-wk high
$281.07
52-wk low
$184.66
EPS
$6.59
Beta
0.21
Shares outstanding
2.41B
No. of employees
138K
Open
$254.43
High
$255.56
Low
$251.50
Mkt. cap
611.61B
Avg. vol.
7.09M
Volume
8.68M
Dividend
2.11%
Quarterly dividend
$1.34
Ex-dividend date
Aug 25, 2026
P/E ratio
38.52
52-wk high
$281.07
52-wk low
$184.66
EPS
$6.59
Beta
0.21
Shares outstanding
2.41B
No. of employees
138K
News stories
From web sources and news partners
About Johnson & Johnson
CEOJoaquin Duato
Employees138K
FoundedJan 1886
HeadquartersNew Brunswick, New Jersey, United States
SectorPharmaceutical industry
Websitejnj.com
Analyst ratings
Based on 18 analysts giving stock ratings to JNJ in the past 3 months
Buy
Buy
12
Hold
5
Sell
1
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for JNJ in the last 3 months.
Highest
Current $253.79
$320.00 (+26.09%)
Average
$278.78 (+9.85%)
Lowest
$110.00 (-56.66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jose Luis Pascual
JLPascual
Sell
Downgraded
$110.00
-56.7%
10/17/2026
David Risinger
Leerink Partners
Buy
Reiterated
$272.00
+7.2%
10/15/2026
Louise Chen
Scotiabank
Buy
Maintained
$305.00
+20.2%
10/14/2026
Trung Huynh
RBC Capital
Buy
Reiterated
$280.00
+10.3%
10/13/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$292.00
+15.1%
10/15/2026
Lee Hambright
Bernstein
Hold
Maintained
$270.00
+6.4%
10/14/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$287.00
+13.1%
10/15/2026
Jason Gerberry
Bank of America Securities
Hold
Maintained
$275.00
+8.4%
10/14/2026
Rick Wise
Stifel Nicolaus
Hold
Maintained
$260.00
+2.4%
10/12/2026
Michael Yee
UBS
Buy
Maintained
$320.00
+26.1%
10/09/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$287.00
+13.1%
10/06/2026
Joanne Wuensch
Citi
Buy
Maintained
$303.00
+19.4%
10/05/2026
Chris Schott
J.P. Morgan
Hold
Maintained
$285.00
+12.3%
09/29/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
$300.00
+18.2%
09/14/2026
Nico Chen
DBS
Hold
Maintained
$270.00
+6.4%
09/11/2026
Morten Herholdt
HSBC
Buy
Maintained
$320.00
+26.1%
09/10/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$287.00
+13.1%
09/09/2026
Asad Haider
Goldman Sachs
Buy
Maintained
$282.00
+11.1%
08/25/2026
David Toung
Argus Research
Buy
Reiterated
$300.00
+18.2%
07/28/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
$280.00
+10.3%
07/16/2026
Jayson Bedford
Raymond James
Buy
Maintained
$265.00
+4.4%
07/16/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
$287.00
+13.1%
07/13/2026
Steve Scala
TD Cowen
Buy
Maintained
$300.00
+18.2%
07/13/2026
Matt Miksic
Barclays
Hold
Reiterated
$255.00
+0.5%
05/13/2026
Hans Engel
Erste Group
Buy
Maintained
-
-
05/05/2026
Josh Jennings
TD Cowen
Buy
Maintained
$250.00
-1.5%
04/23/2026
Danielle Antalffy
UBS
Buy
Reiterated
$280.00
+10.3%
03/17/2026
Last report
Oct 13, 2026
Fiscal period
Q3 2026
$2.59 / $2.52
+2.69%beat
Revenue / Est. (USD)
25.40B / 25.38B
+0.07%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
24.56B
24.06B
25.31B
25.40B
Cost of goods sold
7.81B
8.09B
8.02B
8.10B
Cost of revenue
7.81B
8.09B
8.02B
8.10B
Research and development expenses
4.25B
3.53B
3.65B
4.65B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.61B
5.85B
6.25B
6.28B
Operating expense
10.86B
9.38B
9.91B
10.94B
Total operating expenses
18.68B
17.47B
17.92B
19.03B
Operating income
5.89B
6.60B
7.39B
6.36B
Other non operating income
396.00M
-211.00M
110.00M
-5.78B
EBT including unusual items
4.97B
5.99B
6.75B
34.00M
EBT excluding unusual items
6.03B
6.41B
7.42B
554.00M
Income tax expense
-150.00M
755.00M
1.21B
-176.00M
Effective tax rate
-3.02%
12.60%
17.98%
-517.65%
Other operating expenses
-
-
-
-
Net income
5.12B
5.24B
5.53B
210.00M
Net profit margin
20.83%
21.76%
21.86%
0.83%
Earnings per share
2.46
2.70
2.90
2.59
Interest and investment income
237.00M
229.00M
219.00M
-
Interest expense
-214.00M
-272.00M
-281.00M
-31.00M
Net interest expenses
23.00M
-43.00M
-62.00M
-31.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
7.90B
8.60B
9.35B
8.32B
Gain or loss from assets sale
-132.00M
12.00M
-55.00M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps